Ifeanyichukwu Ifechidere: Rebalanced Haemostasis in Liver Disease
Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospitals NHS Foundation Trust, shared a post on LinkedIn:
“A patient with liver disease has:
- Prolonged PT/INR
- Low fibrinogen
- Thrombocytopenia
So naturally… everyone assumes they’re ‘auto anticoagulated.’
Right?
Not necessarily.
Because one of the most misunderstood concepts in coagulation is this:
Patients with liver disease can bleed And clot.
And if you work in haemostasis long enough, you eventually realise:
- The coagulation profile in liver disease is not simply ‘hypocoagulable.’
- It’s rebalanced haemostasis.
This changes everything.
Yes — the liver produces most clotting factors.
So in liver disease:
PT/INR may become prolonged
Factor levels decrease
Platelets may fall
But here’s what many people overlook:
Natural anticoagulants also decrease:
- Protein C
- Protein S
- Antithrombin
At the same time:
- Factor VIII increases
- von Willebrand factor increases
Meaning?
The haemostatic system is no longer ‘normal’ —
but it may still remain balanced enough to clot.
This is why some patients with severe liver disease:
- Bleed during procedures
And - Develop portal vein thrombosis in the same admission
Sounds contradictory… until you understand rebalanced haemostasis.
And this is where coagulation scientists become essential.
Because if we interpret PT/INR in liver disease the same way we interpret it in warfarin therapy…
we risk misunderstanding the patient completely.
A prolonged INR in liver disease does Not reliably predict bleeding risk.
Read that again.
This is why blindly correcting coagulation numbers without clinical context can sometimes do more harm than good.
As biomedical scientists, our role is not just to report abnormalities.
It’s to understand:
- What the test reflects
- What it does Not reflect
- And how physiology changes the meaning of the result
Because in liver disease…
the coagulation system isn’t broken in one direction.
It’s walking a fragile tightrope between bleeding and thrombosis.”
Find more posts featuring Ifeanyichukwu Ifechidere on Hemostasis Today.
-
Aug 31, 2026, 14:07Ben Dowsing: Can Heart Failure Therapy Be Safely Withdrawn After HER2 Cardiotoxicity Recovery
-
Aug 31, 2026, 14:06Khalid Alfawaz: Signed Consent Doesn’t Always Mean Informed
-
Aug 31, 2026, 14:03Adil Aftab: Anticoagulation in CKD – Key Updates from the 2026 ESC Guidelines
-
Aug 31, 2026, 14:01Isa Oboirien: Why Might Factor XI Inhibition Work Differently in Stroke and ACS?
-
Aug 31, 2026, 13:55Mike Morrissey: Advancing Europe’s Cardiovascular Health Agenda at ESC Congress 2026
-
Aug 31, 2026, 13:44Penilla Gunther: Patient Voices Take Center Stage in Cardiovascular Prevention at ESC Congress 2026
-
Aug 31, 2026, 13:42Mohamed Saleh Gomaa: Master the Latest in PE Management
-
Aug 31, 2026, 13:38Lyn Kleinbach-Reilly: A New Standard for Coagulation Testing in Neonatal Care
-
Aug 31, 2026, 13:36Rafael Gomes: Can Prasugrel Replace Ticagrelor in ACS Treatment?